← Eichor
Study identifier: NCT06475300 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Condition: Non-small Cell Lung Cancer · Nasopharyngeal Carcinoma · Solid Tumor  ·  Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

PhasePhase 2
Planned participants570
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Sa Xiao, PHD  ·  15013238943  ·  xiaosa@baili-pharm.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06475300